Biblio

Filters: Author is Ito, Emiko [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

C

Ohashi F, Miyagawa S, Yasuda S, Miura T, Kuroda T, Itoh M, Kawaji H, Ito E, Yoshida S, Saito A, et al. CXCL4/PF4 is a predictive biomarker of cardiac differentiation potential of human induced pluripotent stem cells. Sci Rep. 2019;9(1):4638.

E

Takeda M, Ito E, Minami K, Harada A, Mochizuki-Oda N, Sawa Y, Miyagawa S. Elimination of residual undifferentiated induced pluripotent stem cells (iPSCs) using irradiation for safe clinical applications of iPSC-derived cardiomyocytes. Biochem Biophys Res Commun. 2021;574:91-96.

Nakazato T, Kawamura T, Uemura T, Liu L, Li J, Sasai M, Harada A, Ito E, Iseoka H, Toda K, et al. Engineered three-dimensional cardiac tissues maturing in a rotating wall vessel bioreactor remodel diseased hearts in rats with myocardial infarction. Stem Cell Reports. 2022.

Ito E, Kawamura A, Kawamura T, Takeda M, Harada A, Mochizuki-Oda N, Sawa Y, Miyagawa S. Establishment of a protocol to administer immunosuppressive drugs for iPS cell-derived cardiomyocyte patch transplantation in a rat myocardial infarction model. Sci Rep. 2023;13(1):10530.

N

Kawamura T, Miyagawa S, Fukushima S, Yoshida A, Kashiyama N, Kawamura A, Ito E, Saito A, Maeda A, Eguchi H, et al. N-Glycans: Phenotypic Homology and Structural Differences between Myocardial Cells and Induced Pluripotent Stem Cell-Derived Cardiomyocytes. PLoS One. 2014;9(10):e111064.

T

Ishida M, Miyagawa S, Saito A, Fukushima S, Harada A, Ito E, Ohashi F, Watabe T, Hatazawa J, Matsuura K, et al. Transplantation of human induced pluripotent stem cell-derived cardiomyocytes is superior to somatic stem cell therapy for restoring cardiac function and oxygen consumption in a porcine model of myocardial infarction. Transplantation. 2018.